Proceeds from the financing will be used to accelerate the development of Tempo’s preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.
Alan Crane, CEO of Tempo Pharmaceuticals and a venture partner at Polaris, said: “This funding allows the continued advancement of our preclinical pipeline towards human clinical trials and will support the generation of data to enable strategic partnerships with leading biotechnology and pharmaceutical companies.”